Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT04879186 |
Other study ID # |
2020/2659 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
July 1, 2015 |
Est. completion date |
July 1, 2021 |
Study information
Verified date |
May 2021 |
Source |
Singapore General Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Contrast induced nephropathy (CIN) is an iatrogenic renal injury following intravascular
administration of radio-opaque contrast media (CM) in susceptible individuals. As the third
leading cause of hospital acquired renal failure, it is associated with increased mortality,
morbidity and prolonged hospital stay. Endovascular procedures have gained greater popularity
in the past decade due to the advance in technology. This has also led to the increased
incidence of CIN after vascular surgeries. We are conducting a retrospective cohort study in
Singapore General Hospital using our perioperative database collected in the past five years.
We will be extracting relevant patient perioperative information including both clinical
diagnosis and lab values. Our primary aim is to establish the incidence of CIN among vascular
patients with or without pre-existing chronic renal impairment undergoing elective peripheral
endovascular angioplasty. Our secondary aims are to establish the risk factors and protective
factors that lead to the development of CIN in vascular patients after peripheral
endovascular angioplasty. We will also be looking at the long-term outcome of patients who
have developed CIN after vascular endovascular angioplasty. The results of the study will
enable us to identify patients at high risk of development of CIN, thus appropriate measures
can be initiated early and help with their recovery process.
Description:
We propose a retrospective single-center cohort study conducted in Singapore general
hospital. Data would be extracted in patients who have undergone peripheral endovascular
angioplasty from 01/01/2015 to 01/01/2020. The data will be extracted from the eHINTs
Perioperative Subject Area without any direct identifiers. The subject area has been
previously curated as part of the SingHealth ODySSEy (On-prem Research Data Science and
Systems Explorer) System. There will be no patient identifier collected and the data
collection administration will not have any access to patient identifier. Waiver of consent
is sought and no patient interaction would be required for the study.
The parameters to be extracted would include preoperative data such as patient demographics
(age, gender, race, BMI), baseline comorbidities including but not limited to: hypertension,
hyperlipidemia, diabetes mellitus, smoking, anemia, heart diseases (previous heart
attack/history of congestive heart failure), preoperative renal function (measured by
baseline Urea, creatinine, electrolytes level Na, K, Cl), preoperative long-term medication
use including ACE inhibitor, ARB, beta-blocker, statin and diuretics and NSAIDS.
Intraoperative data including types of anaesthesia used, operative duration, presence of
intraoperative hypotension. Postoperative parameters such as mortality, length of stay in
hospital and ICU, postoperative renal function measured by urea and creatinine level within 3
days and one month postoperatively.
Statistical analysis will be performed to study the risk factors for CIN in patients
undergoing peripheral endovascular angioplasty.